pteridines has been researched along with Bronchial Hyperreactivity in 1 studies
Bronchial Hyperreactivity: Tendency of the smooth muscle of the tracheobronchial tree to contract more intensely in response to a given stimulus than it does in the response seen in normal individuals. This condition is present in virtually all symptomatic patients with asthma. The most prominent manifestation of this smooth muscle contraction is a decrease in airway caliber that can be readily measured in the pulmonary function laboratory.
| Excerpt | Relevance | Reference |
|---|---|---|
| " For this reason, in a series of preclinical studies, we tested the potential of a recently developed small-molecule inhibitor of these two isoforms, TG100-115 [3-[2,4-diamino-6-(3-hydroxyphenyl)pteridin-7-yl]phenol], as a form of anti-inflammatory therapy for respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD)." | 7.75 | Aerosolized phosphoinositide 3-kinase gamma/delta inhibitor TG100-115 [3-[2,4-diamino-6-(3-hydroxyphenyl)pteridin-7-yl]phenol] as a therapeutic candidate for asthma and chronic obstructive pulmonary disease. ( Acevedo, LM; Cheresh, DA; Dellamary, L; Dneprovskaia, E; Doukas, J; Eide, L; Martin, M; Noronha, G; Racanelli-Layton, A; Soll, R; Stebbins, K; Wrasidlo, W, 2009) |
| " For this reason, in a series of preclinical studies, we tested the potential of a recently developed small-molecule inhibitor of these two isoforms, TG100-115 [3-[2,4-diamino-6-(3-hydroxyphenyl)pteridin-7-yl]phenol], as a form of anti-inflammatory therapy for respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD)." | 3.75 | Aerosolized phosphoinositide 3-kinase gamma/delta inhibitor TG100-115 [3-[2,4-diamino-6-(3-hydroxyphenyl)pteridin-7-yl]phenol] as a therapeutic candidate for asthma and chronic obstructive pulmonary disease. ( Acevedo, LM; Cheresh, DA; Dellamary, L; Dneprovskaia, E; Doukas, J; Eide, L; Martin, M; Noronha, G; Racanelli-Layton, A; Soll, R; Stebbins, K; Wrasidlo, W, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Doukas, J | 1 |
| Eide, L | 1 |
| Stebbins, K | 1 |
| Racanelli-Layton, A | 1 |
| Dellamary, L | 1 |
| Martin, M | 1 |
| Dneprovskaia, E | 1 |
| Noronha, G | 1 |
| Soll, R | 1 |
| Wrasidlo, W | 1 |
| Acevedo, LM | 1 |
| Cheresh, DA | 1 |
1 other study available for pteridines and Bronchial Hyperreactivity
| Article | Year |
|---|---|
Aerosolized phosphoinositide 3-kinase gamma/delta inhibitor TG100-115 [3-[2,4-diamino-6-(3-hydroxyphenyl)pteridin-7-yl]phenol] as a therapeutic candidate for asthma and chronic obstructive pulmonary disease.
Topics: Administration, Intranasal; Aerosols; Animals; Anti-Inflammatory Agents; Asthma; Bronchial Hyperreac | 2009 |